Ignite Creation Date:
2025-12-25 @ 12:40 AM
Ignite Modification Date:
2025-12-25 @ 10:50 PM
Study NCT ID:
NCT01265667
Status:
COMPLETED
Last Update Posted:
2020-11-18
First Post:
2010-12-09
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Trial of CF101 to Treat Patients With Psoriasis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011565', 'term': 'Psoriasis'}], 'ancestors': [{'id': 'D017444', 'term': 'Skin Diseases, Papulosquamous'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C478920', 'term': 'CF101'}, {'id': 'C084956', 'term': "N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine"}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'zivit@canfite.co.il', 'phone': '972-3-9241114', 'title': 'Zivit Harpaz', 'organization': 'Can-Fite BioPharma Ltd'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': '16 weeks', 'description': 'All adverse events were collected and verbatim terms were coded via MedDRA dictionary', 'eventGroups': [{'id': 'EG000', 'title': 'CF101 2 mg', 'description': 'CF101: orally q12h', 'otherNumAtRisk': 145, 'otherNumAffected': 24, 'seriousNumAtRisk': 145, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Placebo', 'description': 'Placebo: orally q12h', 'otherNumAtRisk': 148, 'otherNumAffected': 15, 'seriousNumAtRisk': 148, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 145, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.0'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 145, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.0'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 145, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.0'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 145, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.0'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 145, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 145, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.0'}, {'term': 'Dry mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 145, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 145, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.0'}, {'term': 'Type 2 diabetes mellitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 145, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 145, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.0'}, {'term': 'Haematuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 145, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.0'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 145, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 148, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.0'}], 'frequencyThreshold': '1'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '144', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'CF101 2 mg', 'description': 'CF101: orally q12h'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo: orally q12h'}], 'classes': [{'categories': [{'measurements': [{'value': '12', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '12 weeks', 'description': 'Achievement of PASI 75 indicates a 75% reduction in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the Intent-to-treat (ITT) Population'}, {'type': 'SECONDARY', 'title': 'Number of Subjects Achieving PGA of 0 or 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '144', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'CF101 2 mg', 'description': 'CF101: orally q12h'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo: orally q12h'}], 'classes': [{'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '16 weeks', 'description': "PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe)", 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ITT population'}, {'type': 'SECONDARY', 'title': 'Numberof Patients Achieving Psoriasis Area and Severity (PASI) Score of 50 or 75', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '144', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'CF101 2 mg', 'description': 'CF101: orally q12h'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo: orally q12h'}], 'classes': [{'categories': [{'measurements': [{'value': '31', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '16 weeks', 'description': 'Achievement of PASI 50 or 75 indicates a 50% and 75% reduction respectively in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis performed of the ITT population'}, {'type': 'SECONDARY', 'title': 'Nature and Frequency of Adverse Events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '145', 'groupId': 'OG000'}, {'value': '148', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'CF101 2 mg', 'description': 'CF101: orally q12h'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo: orally q12h'}], 'classes': [{'title': 'Any', 'categories': [{'measurements': [{'value': '37', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}]}, {'title': 'Gastrointestinal disorders', 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}]}, {'title': 'Infections and infestations', 'categories': [{'measurements': [{'value': '10', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}]}, {'title': 'Musculoskeletal and connective tissue disorders', 'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}]}, {'title': 'Nervous system disorders', 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Renal and urinary disorders', 'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '32 weeks', 'description': 'Assessment of safety of CF101 in this patient population by gathering adverse event data based on history, vital signs, physical examination, and laboratory data', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'CF101 2 mg', 'description': 'CF101: orally q12h'}, {'id': 'FG001', 'title': 'Placebo', 'description': 'Placebo: orally q12h'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '145'}, {'groupId': 'FG001', 'numSubjects': '148'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '125'}, {'groupId': 'FG001', 'numSubjects': '135'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '20'}, {'groupId': 'FG001', 'numSubjects': '13'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '145', 'groupId': 'BG000'}, {'value': '148', 'groupId': 'BG001'}, {'value': '293', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'CF101 2mg', 'description': 'Oral tablets given every 12 hours for 16 weeks'}, {'id': 'BG001', 'title': 'Placebo', 'description': 'Oral tablets given every 12 hours for 16 weeks'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '48.3', 'spread': '13.57', 'groupId': 'BG000'}, {'value': '50.0', 'spread': '13.96', 'groupId': 'BG001'}, {'value': '49.2', 'spread': '13.77', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '54', 'groupId': 'BG000'}, {'value': '53', 'groupId': 'BG001'}, {'value': '107', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '91', 'groupId': 'BG000'}, {'value': '95', 'groupId': 'BG001'}, {'value': '186', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2', 'PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 293}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2011-07'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-10', 'completionDateStruct': {'date': '2015-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-10-31', 'studyFirstSubmitDate': '2010-12-09', 'resultsFirstSubmitDate': '2017-06-01', 'studyFirstSubmitQcDate': '2010-12-22', 'lastUpdatePostDateStruct': {'date': '2020-11-18', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2017-08-20', 'studyFirstPostDateStruct': {'date': '2010-12-23', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2017-09-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2015-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks', 'timeFrame': '12 weeks', 'description': 'Achievement of PASI 75 indicates a 75% reduction in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)'}], 'secondaryOutcomes': [{'measure': 'Number of Subjects Achieving PGA of 0 or 1', 'timeFrame': '16 weeks', 'description': "PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe)"}, {'measure': 'Numberof Patients Achieving Psoriasis Area and Severity (PASI) Score of 50 or 75', 'timeFrame': '16 weeks', 'description': 'Achievement of PASI 50 or 75 indicates a 50% and 75% reduction respectively in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)'}, {'measure': 'Nature and Frequency of Adverse Events', 'timeFrame': '32 weeks', 'description': 'Assessment of safety of CF101 in this patient population by gathering adverse event data based on history, vital signs, physical examination, and laboratory data'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Psoriasis', 'Plaque psoriasis'], 'conditions': ['Plaque Psoriasis']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://www.canfite.com/', 'label': 'Can-Fite BioPharma website'}]}, 'descriptionModule': {'briefSummary': 'Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.', 'detailedDescription': 'Eligible patients will be randomly assigned to parallel dosing groups of CF101 2 mg or matching placebo tablets twice daily (BID) in a 1:1 ratio for the 16-week controlled treatment period. Approximately 94 patients will be assigned to each group.\n\nMedication will be taken orally BID for 16 weeks in a double-blinded fashion. At the end of 16 weeks, all patients assigned to CF101 will continue CF101, while patients originally assigned to placebo will be reassigned to CF101.\n\nAssessment of peripheral blood mononuclear cell (PBMC) adenosine A3 receptor (A3AR) expression at baseline and during treatment with CF101 in selected sites.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Male or female, 18 to 80 years of age, inclusive\n* Diagnosis of moderate-to-severe chronic plaque-type psoriasis with body surface area involvement ≥10%\n* Duration of psoriasis of at least 6 months\n* Physician global assessment (PGA) ≥3\n* Candidate for systemic treatment or phototherapy for psoriasis\n* Electrocardiogram (ECG) is normal\n* Females of child-bearing potential must have a negative serum pregnancy test\n* Females of child-bearing potential must be willing to use 2 methods of contraception\n* Ability to complete the study in compliance with the protocol\n* Ability to understand and provide written informed consent.\n\nExclusion Criteria:\n\n* Erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis\n* Treatment with systemic retinoids, corticosteroids, or immunosuppressive agents within 4 weeks of the Baseline visit\n* Treatment with high potency topical corticosteroids, keratolytics, or coal tar within 2 weeks of the Baseline visit\n* Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit\n* Treatment with a biological agent within a period of time equal to 5 times its circulating half-life\n* Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the Baseline visit\n* Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal\n* Liver aminotransferase levels greater than the laboratory's upper limit of normal\n* Significant acute or chronic medical or psychiatric illness\n* Participation in another investigational drug or vaccine trial concurrently or within 30 days prior to Screening visit."}, 'identificationModule': {'nctId': 'NCT01265667', 'briefTitle': 'Trial of CF101 to Treat Patients With Psoriasis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Can-Fite BioPharma'}, 'officialTitle': 'A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis', 'orgStudyIdInfo': {'id': 'CF101-202PS'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'CF101 2 mg', 'description': 'CF101 2mg oral tablets', 'interventionNames': ['Drug: CF101']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Placebo oral tablets', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'CF101', 'type': 'DRUG', 'otherNames': ['IB-MECA'], 'description': 'orally q12h', 'armGroupLabels': ['CF101 2 mg']}, {'name': 'Placebo', 'type': 'DRUG', 'otherNames': ['Dummy pills'], 'description': 'orally q12h', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Mount Sinai School of Medicine', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '5800,', 'city': 'Pleven', 'country': 'Bulgaria', 'facility': 'UMHAT "G.stranski"', 'geoPoint': {'lat': 43.41791, 'lon': 24.61666}}, {'zip': '1407', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'MHAT "Tokuda hospital Sofia"', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1463', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'DCC "Fokus-5"-MIOC, EOOD', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1606', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Military Medical Acdemy (MMA)', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1632,', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'MHAT "Doverie"', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'City Center for Skin and Venereal Disease', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '6003', 'city': 'Stara Zagora', 'country': 'Bulgaria', 'facility': 'Multiprofile Hospital for Active Ttreatment', 'geoPoint': {'lat': 42.43205, 'lon': 25.64262}}, {'zip': '9010,', 'city': 'Varna', 'country': 'Bulgaria', 'facility': 'MHAT Varna at MMA Sofia', 'geoPoint': {'lat': 43.21912, 'lon': 27.91024}}, {'city': 'Afula', 'country': 'Israel', 'facility': 'Haemek Medical Center', 'geoPoint': {'lat': 32.60907, 'lon': 35.2892}}, {'zip': '31096', 'city': 'Haifa', 'country': 'Israel', 'facility': 'Rambam Medical Center', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '49100', 'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Rabin Medical Center', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'city': 'Bucharest', 'country': 'Romania', 'facility': 'Centrul Medical Euromed', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'city': 'Bucharest', 'country': 'Romania', 'facility': 'Spitalul Clinic Dermato-Venerice', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'city': 'Cluj-Napoca', 'country': 'Romania', 'facility': 'Emergency County Clinical Hospital', 'geoPoint': {'lat': 46.76667, 'lon': 23.6}}, {'zip': '900622', 'city': 'Constanța', 'country': 'Romania', 'facility': 'Spitalul Clinic Judetean de Urgenta Constanta', 'geoPoint': {'lat': 44.18073, 'lon': 28.63432}}, {'zip': '700368,', 'city': 'Iași', 'country': 'Romania', 'facility': 'Spit Clinic Judetean de Urgenta Sf Spiridon Iasi', 'geoPoint': {'lat': 47.16667, 'lon': 27.6}}, {'city': 'Sibiu', 'country': 'Romania', 'facility': 'County Clinical Emergency Hospital', 'geoPoint': {'lat': 45.8, 'lon': 24.15}}], 'overallOfficials': [{'name': 'Michael H Silverman, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Can-Fite BioPharma'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Can-Fite BioPharma', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}